

# GARPR Online Reporting Tool

---

## Uganda - 2014

### 0 Narrative Report and Cover Sheet

#### 1) Which institutions/entities were responsible for filling out the indicator forms?

a) **NAC or equivalent:** Yes

b) **NAP:** No

c) **Others:** Yes

**If Others, please specify:** Ministry of Health

#### 2) With inputs from

**Ministry of Education:** Yes

**Ministry of Health:** Yes

**Ministry of Labour:** Yes

**Ministry of Foreign Affairs:** No

**Other Ministry:** No

**If Other Ministry, please specify:**

**Civil society organizations:** Yes

**People living with HIV:** Yes

**Private sector:** Yes

**United Nations organizations:** Yes

**Bilateral organizations:** Yes

**International NGOs:** Yes

**Others:**

**If Others, please specify:**

**3) Was the report discussed in a large forum?:** Yes

**4) Are the survey results stored centrally?:** Yes

5) Are data available for public consultation?: Yes

**6) Who is the person responsible for submission of the report?**

**Name(s) / title(s):** : Dr. Christine J.D Ondo, Director General Uganda AIDS Commission

**Address(es):** : Dr. Ondo D.J. Christine Director General Uganda AIDS Commission Plot 1 - 3 Salim Bey Road, Ntinda P.O.Box 10779 KAMPALA - Uganda Tel: Office: +256-414-288065; +256-414-288989 Mob: +256-772-428346 +256-758500300 Office Email: condoa@uac.go.ug; Private Email: jondoa@hotmail.com; titijoe2020@gmail.com; Website: www.aidsuganda.org

**Email(s):**: condoa@uac.go.ug

**Telephone(s):** : Tel: +256-414-288065

**1.1 Young People: Knowledge about HIV prevention**

**is indicator/topic relevant?:** Yes

**Are new data available? (Please do not repeat data that was reported in a prior year):** No

**Data measurement tool / source:**

**Other measurement tool / source:**

**From date:**

**To date:**

**Additional information related to entered data. e.g. reference to primary data source, methodological concerns::**

**Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::**

**Sample size - Number of Survey Respondents:**

**Correct answer to all five questions**

	All (15-24)	All Males (15-24)	Males (15-19)	Males (20-24)	All Females (15-24)	Females (15-19)	Females (20-24)
<b>Percentage (%) :</b> Percentage of respondents aged 15-24 years who gave the correct answer to all five questions							
<b>Numerator :</b> Number of respondents aged 15-24 years who gave the correct answer to all five questions							
<b>Denominator :</b> Number of all respondents aged 15-24							

**Correct answer to question 1 "Can the risk of HIV transmission be reduced by having sex with only one uninfected partner who has no other partners?"**

	All (15-24)	All Males (15-24)	Males (15-19)	Males (20-24)	All Females (15-24)	Females (15-19)	Females (20-24)
<b>Percentage (%) :</b> Percentage of respondents who gave a correct answer to question 1							
<b>Numerator :</b> Numerator Number of respondents/population who gave correct answer to question 1							
<b>Denominator :</b> Number of all respondents age 15-24							

**Correct answer to question 2 "Can a person reduce the risk fo getting HIV by using a condom every time they have sex?"**

	All (15-24)	All Males (15-24)	Males (15-19)	Males (20-24)	All Females (15-24)	Females (15-19)	Females (20-24)
<b>Percentage (%) :</b> Percentage of respondents who gave a correct answer to question 2							
<b>Numerator :</b> Number of respondents/population who gave correct answer to question 2							
<b>Denominator :</b> Number of all respondents age 15-24							

**Correct answer to question 3 "Can a healthy-looking person have HIV" ?**

	All (15-24)	All Males (15-24)	Males (15-19)	Males (20-24)	All Females (15-24)	Females (15-19)	Females (20-24)
<b>Percentage (%) :</b> Percentage of respondents who gave a correct answer to question 3							
<b>Numerator :</b> Number of respondents/population who gave correct answer to question 3							
<b>Denominator :</b> Number of all respondents age 15-24							

**Correct answer to question 4 "Can a person get HIV from mosquito bites?" (or country specific question)**

	All (15-24)	All Males (15-24)	Males (15-19)	Males (20-24)	All Females (15-24)	Females (15-19)	Females (20-24)
<b>Percentage (%) :</b> Percentage of respondents who gave a correct answer to question 4							
<b>Numerator :</b> Number of respondents/population who gave correct answer to question 4							
<b>Denominator :</b> Number of all respondents age 15-24							

**Correct answer to question 5 "Can a person get HIV from sharing food with someone who is infected?" (or country specific question)**

	All (15-24)	All Males (15-24)	Males (15-19)	Males (20-24)	All Females (15-24)	Females (15-19)	Females (20-24)
<b>Percentage (%) :</b> Percentage of respondents who gave a correct answer to question 5							
<b>Numerator :</b> Number of respondents/population who gave correct answer to question 5							
<b>Denominator :</b> Number of all respondents age 15-24							

**1.2 Sex before the age of 15**

**is indicator/topic relevant?:** Yes

**Are new data available? (Please do not repeat data that was reported in a prior year):** No

**Data measurement tool / source:**

**Other measurement tool / source:**

**From date:**

**To date:**

**Additional information related to entered data. e.g. reference to primary data source, methodological concerns::**

**Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::**

**Sample size - Number of Survey Respondents:**

	All (15-24)	All Males (15-24)	Males (15-19)	Males (20-24)	All Females (15-24)	Females (15-19)	Females (20-24)
<b>Percentage (%) :</b> Percentage of young women and men aged 15-24 who have had sexual intercourse before the age of 15							
<b>Numerator :</b> Number of respondents (aged 15-24 years) who report the age at which they first had sexual intercourse as under 15 years							
<b>Denominator :</b> Number of all respondents aged 15-24 years							

### 1.3 Multiple sexual partners

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): No

Data measurement tool / source:

Other measurement tool / source:

From date:

To date:

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::

Sample size - Number of Survey Respondents:

	All ages	Males (all ages)	Males (15-19)	Males (20-24)	Males (25-49)	Females (all ages)	Females (15-19)	Females (20-24)	Females (25-49)
<b>Percentage (%) :</b> Percentage of women and men aged 15-49 who have had sexual intercourse with more than one partner in the past 12 months									
<b>Numerator :</b> Number of respondents aged 15-49 who have had sexual intercourse with more than one partner in the last 12 months									
<b>Denominator :</b> Number of all respondents aged 15-49									

### 1.4 Condom use at last sex among people with multiple sexual partnerships

is indicator/topic relevant?: Yes

**Are new data available? (Please do not repeat data that was reported in a prior year):** No

**Data measurement tool / source:**

**Other measurement tool / source:**

**From date:**

**To date:**

**Additional information related to entered data. e.g. reference to primary data source, methodological concerns::**

**Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::**

**Sample size - Number of Survey Respondents:**

	All ages	Males (all ages)	Males (15-19)	Males (20-24)	Males (25-49)	Females (all ages)	Females (15-19)	Females (20-24)	Females (25-49)
<b>Percentage (%) :</b> Percentage of women and men aged 15-49 who had more than one partner in the past 12 months who used a condom during their last sexual intercourse									
<b>Numerator :</b> Number of respondents (aged 15-49) who reported having had more than one sexual partner in the last 12 months who also reported that a condom was used the last time they had sex									
<b>Denominator :</b> Number of respondents (15-49) who reported having had more than one sexual partner in the last 12 months									

## 1.5 HIV testing in the general population

**is indicator/topic relevant?:** Yes

**Are new data available? (Please do not repeat data that was reported in a prior year):** No

**Data measurement tool / source:**

**Other measurement tool / source:**

**From date:**

**To date:**

**Additional information related to entered data. e.g. reference to primary data source, methodological concerns::**

**Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::**

**Sample size - Number of Survey Respondents:**

	All ages	Males (all ages)	Males (15-19)	Males (20-24)	Males (25-49)	Females (all ages)	Females (15-19)	Females (20-24)	Females (25-49)
<b>Percentage (%) :</b> Percentage of women and men aged 15-49 who received an HIV test in the past 12 months and know their results									
<b>Numerator :</b> Number of respondents aged 15-49 who have been tested for HIV during the last 12 months and who know their results									
<b>Denominator :</b> Number of all respondents aged 15-49, including those who have never heard of HIV or AIDS.									

## 1.6 HIV prevalence in young people

**is indicator/topic relevant?:** Yes

**Are new data available? (Please do not repeat data that was reported in a prior year):** No

**Data measurement tool / source:**

**Other measurement tool / source:**

**From date:**

**To date:**

**Additional information related to entered data. e.g. reference to primary data source, methodological concerns::**

**Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::**

**Sample size - Number of Survey Respondents:**

	15-24	15-19	20-24
<b>Percentage (%) :</b> Percentage of young people aged 15-24 who are living with HIV			
<b>Numerator :</b> Number of antenatal clinic attendees (aged 15-24) tested whose HIV test results are positive			
<b>Denominator :</b> Number of antenatal clinic attendees (aged 15-24) tested for their HIV infection status			

## B Size estimations for key populations

### Sex workers

**Have you performed population size estimations for sex workers?:** No

**If yes, when was the latest estimation performed? (year):**

**If yes, for which region was the last estimation performed?:**

If yes, what was the method used to perform the estimation?:

If yes, what was the size estimation?:

Comments:

### **Men who have sex with men**

Have you performed population size estimations for men who have sex with men?: No

If yes, when was the latest estimation performed? (year):

If yes, for which region was the last estimation performed?:

If yes, what was the method used to perform the estimation?:

If yes, what was the size estimation?:

Comments :

### **People who inject drugs**

Have you performed population size estimations for people who inject drugs?: No

If yes, when was the latest estimation performed? (year):

If yes, for which region was the last estimation performed?:

If yes, what was the method used to perform the estimation?:

If yes, what was the size estimation?:

Comments:

Other key populations (please specify):

Have you performed population size estimations for other key populations?: No

If yes, when was the latest estimation performed? (year):

If yes, what was the size estimation?:

If yes, for which region was the last estimation performed?:

If yes, what was the method used to perform the estimation?:

Comments :

### **B.1 Sex workers**

Case definition: None



Number of sites: 0

Information about the sites:

Sampling method:

Are the data representative of the entire country?: No

## 1.7 Sex Workers: prevention programmes

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): No

Data measurement tool / source:

Other measurement tool / source:

From date:

To date:

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::

Sample size - Number of Survey Respondents:

### Correct answer to both questions

	All	Males	Females	Transwoman	<25	25+
<b>Percentage (%) :</b> Percentage of sex workers who replied "yes" to both questions						
<b>Numerator :</b> Number sex workers who replied "yes" to both questions						
<b>Denominator :</b> Total number of sex workers surveyed						

### Correct answer to question 1 "Do you know where you can go if you wish to receive an HIV test?"

	All	Males	Females	Transwoman	<25	25+
<b>Percentage (%) :</b> Percentage of sex workers who replied "yes" to question 1						
<b>Numerator :</b> Number sex workers who replied "yes" to question 1						
<b>Denominator :</b> Total number of sex workers surveyed						

### Correct answer to question 2 "In the last twelve months, have you been given condoms?"

	All	Males	Females	Transwoman	<25	25+
<b>Percentage (%) :</b> Percentage of sex workers who replied "yes" to question 2						
<b>Numerator :</b> Number of sex workers who replied "yes" to question 2						
<b>Denominator :</b> Total number of sex workers surveyed						

## 1.8 Sex workers: condom use

**is indicator/topic relevant?:** Yes

**Are new data available? (Please do not repeat data that was reported in a prior year):** No

**Data measurement tool / source:**

**Other measurement tool / source:**

**From date:**

**To date:**

**Additional information related to entered data. e.g. reference to primary data source, methodological concerns::**

**Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::**

**Sample size - Number of Survey Respondents:**

	All	Males	Females	Transwoman	<25	25+
<b>Percentage (%) :</b> Percentage of sex workers reporting the use of a condom with their most recent client						
<b>Numerator :</b> Number of sex workers who reported that a condom was used with their last client						
<b>Denominator :</b> Number of sex workers who reported having commercial sex in the last 12 months						

**Total and disaggregated by age**

**Please enter the breakdown per site below. [Add as many as needed]**

Site	Sample size	Percentage (%)	All - Numerator	All - Denominator	<25 - Numerator	<25 - Denominator	25+ - Numerator	25+ - Denominator
------	-------------	----------------	-----------------	-------------------	-----------------	-------------------	-----------------	-------------------

**Disaggregated by sex**

**Please enter the breakdown per site in the same order as in the table above. [Add as many as needed]**

Site	Males - Numerator	Males - Denominator	Females - Numerator	Females - Denominator	Males (<25) - Numerator	Males (<25) - Denominator	Females (<25) - Numerator	Females (<25) - Denominator
------	-------------------	---------------------	---------------------	-----------------------	-------------------------	---------------------------	---------------------------	-----------------------------

## 1.9 HIV testing in sex workers

**is indicator/topic relevant?:** Yes

**Are new data available? (Please do not repeat data that was reported in a prior year):** No

**Data measurement tool / source:**

**Other measurement tool / source:**

**From date:**

**To date:**

**Additional information related to entered data. e.g. reference to primary data source, methodological concerns::**

**Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::**

**Sample size - Number of Survey Respondents:**

	All	Males	Females	Transwoman	<25	25+
<b>Percentage (%) :</b> Percentage of sex workers who received an HIV test in the past 12 months and know their results						
<b>Numerator :</b> Number of sex workers who have been tested for HIV during the last 12 months and who know their results						
<b>Denominator :</b> Number of sex workers included in the sample						

**Total and disaggregated by age**

**Please enter the breakdown per site below. [Add as many as needed]**

Site	Sample size	Percentage (%)	All - Numerator	All - Denominator	<25 - Numerator	<25 - Denominator	25+ - Numerator	25+ - Denominator
------	-------------	----------------	-----------------	-------------------	-----------------	-------------------	-----------------	-------------------

**Disaggregated by sex**

**Please enter the breakdown per site in the same order as in the table above. [Add as many as needed]**

Site	Males - Numerator	Males - Denominator	Females - Numerator	Females - Denominator	Males (<25) - Numerator	Males (<25) - Denominator	Females (<25) - Numerator	Females (<25) - Denominator
------	-------------------	---------------------	---------------------	-----------------------	-------------------------	---------------------------	---------------------------	-----------------------------

## 1.10 HIV prevalence in sex workers

**is indicator/topic relevant?:** Yes

**Are new data available? (Please do not repeat data that was reported in a prior year):** No

**Data measurement tool / source:**

**Other measurement tool / source:**

**From date:**

**To date:**

**Additional information related to entered data. e.g. reference to primary data source, methodological concerns::**

**Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::**

**Sample size - Number of Survey Respondents:**

	All	Males	Females	Transwoman	<25	25+
<b>Percentage (%) :</b> Percentage of sex workers who are living with HIV						
<b>Numerator :</b> Number of sex workers who test positive for HIV						
<b>Denominator :</b> Number of sex workers tested for HIV						

### Total and disaggregated by age

Please enter the breakdown per site below. [Add as many as needed]

Site	Sample size	Percentage (%)	All - Numerator	All - Denominator	<25 - Numerator	<25 - Denominator	25+ - Numerator	25+ - Denominator
------	-------------	----------------	-----------------	-------------------	-----------------	-------------------	-----------------	-------------------

### Disaggregated by sex

Please enter the breakdown per site in the same order as in the table above. [Add as many as needed]

Site	Males - Numerator	Males - Denominator	Females - Numerator	Females - Denominator	Males (<25) - Numerator	Males (<25) - Denominator	Females (<25) - Numerator	Females (<25) - Denominator
------	-------------------	---------------------	---------------------	-----------------------	-------------------------	---------------------------	---------------------------	-----------------------------

## B.2 Men who have sex with men

Case definition: None

Number of sites: 0

Information about the sites:

Sampling method:

Are the data representative of the entire country?: No

### 1.11 Men who have sex with men: prevention programmes

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): No

Data measurement tool / source:

Other measurement tool / source:

From date:

To date:

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::

Sample size - Number of Survey Respondents:

Correct answer to both questions

	All	<25	25+
<b>Percentage (%)</b> : Percentage of MSM who replied "yes" to both questions			
<b>Numerator</b> : Number MSM who replied "yes" to both questions			
<b>Denominator</b> : Total number of MSM surveyed			

**Correct answer to question 1 "Do you know where you can go if you wish to receive an HIV test?"**

	All	<25	25+
<b>Percentage (%)</b> : Percentage of MSM who replied "yes" to question 1			
<b>Numerator</b> : Number MSM who replied "yes" to question 1			
<b>Denominator</b> : Total number of MSM surveyed			

**Correct answer to question 2 "In the last twelve months, have you been given condoms?"**

	All	<25	25+
<b>Percentage (%)</b> : Percentage of MSM who replied "yes" to question 2			
<b>Numerator</b> : Number MSM who replied "yes" to question 2			
<b>Denominator</b> : Total number of MSM surveyed			

## 1.12 Men who have sex with men: condom use

**is indicator/topic relevant?:** Yes

**Are new data available? (Please do not repeat data that was reported in a prior year):** No

**Data measurement tool / source:**

**Other measurement tool / source:**

**From date:**

**To date:**

**Additional information related to entered data. e.g. reference to primary data source, methodological concerns::**

**Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::**

**Sample size - Number of Survey Respondents:**

	All	<25	25+
<b>Percentage (%)</b> : Percentage of MSM who reported that a condom was used the last time they had anal sex			
<b>Numerator</b> : Number of MSM who reported that a condom was used the last time they had anal sex			
<b>Denominator</b> : Number of MSM who reported having had anal sex with a male partner in the last six months			

**Total and disaggregated by age**

**Please enter the breakdown per site below. [Add as many as needed]**

Site	Sample size	Percentage (%)	All - Numerator	All - Denominator	<25 - Numerator	<25 - Denominator	25+ - Numerator	25+ - Denominator
------	-------------	----------------	-----------------	-------------------	-----------------	-------------------	-----------------	-------------------

## 1.13 HIV testing in men who have sex with men

**is indicator/topic relevant?:** Yes

**Are new data available? (Please do not repeat data that was reported in a prior year):** No

**Data measurement tool / source:**

**Other measurement tool / source:**

**From date:**

**To date:**

**Additional information related to entered data. e.g. reference to primary data source, methodological concerns::**

**Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::**

**Sample size - Number of Survey Respondents:**

	All	<25	25+
<b>Percentage (%) :</b> Percentage of men who have sex with men who received an HIV test in the past 12 months and know their results			
<b>Numerator :</b> Number of men who have sex with men who have been tested for HIV during the last 12 months and who know their results			
<b>Denominator :</b> Number of men who have sex with men included in the sample			

**Total and disaggregated by age**

**Please enter the breakdown per site below. [Add as many as needed]**

Site	Sample size	Percentage (%)	All - Numerator	All - Denominator	<25 - Numerator	<25 - Denominator	25+ - Numerator	25+ - Denominator
------	-------------	----------------	-----------------	-------------------	-----------------	-------------------	-----------------	-------------------

### 1.14 HIV prevalence in men who have sex with men

**is indicator/topic relevant?:** Yes

**Are new data available? (Please do not repeat data that was reported in a prior year):** No

**Data measurement tool / source:**

**Other measurement tool / source:**

**From date:**

**To date:**

**Additional information related to entered data. e.g. reference to primary data source, methodological concerns::**

**Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::**

**Sample size - Number of Survey Respondents:**

	All	<25	25+
<b>Percentage (%) :</b> Percentage of men who have sex with men risk who are living with HIV			
<b>Numerator :</b> Number of MSM who test positive for HIV			
<b>Denominator :</b> Number of MSM tested for HIV			

**Total and disaggregated by age**

**Please enter the breakdown per site below. [Add as many as needed]**

Site	Sample size	Percentage (%)	All - Numerator	All - Denominator	<25 - Numerator	<25 - Denominator	25+ - Numerator	25+ - Denominator
------	-------------	----------------	-----------------	-------------------	-----------------	-------------------	-----------------	-------------------

## 1.15 Number of health facilities that provide HIV testing and counselling services

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): Yes

Data measurement tool / source: Central register of all T&C sites

Other measurement tool / source:

From date: 01/01/2014

To date: 31/12/2014

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

There is no inventory for HCT sites but data was analysed from the number of sites that ever reported in the period 01 Jan 2014 to 31 Dec 2014

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::

### Total

	Data value
Number of health facilities that provide HIV testing and counselling services	3365
Public sector	
Private sector	
Unknown	

### Disaggregation by type of health facility

	Data value
Government health facilities	
NGOs	
CBOs	
Mission hospitals	
Private health facilities	
Other : Please specify in 'Additional information'	

### Disaggregation by type of services offered

	Data value
TB clinic	
STI Clinic	
Other : Please specify in 'Additional information'	

## 1.16 HIV Testing and counselling in women and men

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): Yes

Data measurement tool / source: Please specify the data measurement tool below

Other measurement tool / source: HMIS

From date: 01/01/2014

To date: 31/12/2014

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

Not disaggregated by age group

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::

### Children aged 0-14 years

	Total	Males	Females	Gender unknown
<b>Number - all children :</b> Number of children who received HIV testing and counselling in the past 12 months and know their results	926141	454168	4719734	0
< 1				
1 - 9				
10 - 14				
<b>Number - all children : HIV+</b> out of the number tested	14738	6595	8143	0

### Adults aged 15 and older

	Total	Males	Females	Gender unknown
<b>Number - all adults :</b> Number of adults who received HIV testing and counselling in the past 12 months and know their results	8638851	2801866	5836985	0
15 - 19				
20 - 24				
25 - 49				
50+				
<b>Number - all adults : HIV+</b> out of the number tested	324323	101686	222637	0

### Pregnant women (out of total number above)

	Females (15+)	Females (15-19)	Females (20-24)	Females (25+)
<b>Number :</b> Number of pregnant women aged 15 and older (out of the total number above) who received testing and counselling in the past 12 months and received their results	1727465			

### 1.16.1 Rapid HIV test kits stock-outs

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): Yes

Data measurement tool / source: Other

Other measurement tool / source: DHIS tool

From date: 01/01/2014

To date: 31/12/2014

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::

	Total
<b>Percentage (%) :</b> Percentage of health facilities dispensing HIV rapid test kits that experienced a stock-out in the last 12 months	11
<b>Numerator :</b> Number of health facilities dispensing rapid HIV test kits (if applicable) that experienced a stock-out in the last 12 months	376
<b>Denominator :</b> Total number of health facilities dispensing rapid HIV test kits	3365

### 1.17.1 Percentage of women accessing antenatal care (ANC) services who were tested for syphilis

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): Yes

Data measurement tool / source: National programme records of lists of facilities



**Other measurement tool / source:** HMIS

**From date:** 01/01/2014

**To date:** 31/12/2014

**Additional information related to entered data. e.g. reference to primary data source, methodological concerns::**

Women test at any time of ANC, depending on test Kits availability, thus no data for 1st ANC

**Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::**

**Are the data representative of the entire country?:** No

**If no, please describe:** Test kits for syphilis not available all the time, thus missed opportunities

#### At first ANC visit

	Total
<b>Percentage (%)</b> : Percentage of women accessing antenatal care (ANC) services who were tested for syphilis at first ANC visit	
<b>Numerator</b> : Number of women attending ANC services who were tested for syphilis at first ANC visit	
<b>Denominator</b> : Number of women attending ANC services	1561477

#### At any ANC visit

	Total
<b>Percentage (%)</b> : Percentage of women accessing antenatal care (ANC) services who were tested for syphilis at any ANC visit	17
<b>Numerator</b> : Number of women attending ANC services who were tested for syphilis at any ANC visit	268845
<b>Denominator</b> : Number of women attending ANC services	1561477

### 1.17.2 Percentage of antenatal care attendees who were positive for syphilis

**is indicator/topic relevant?:** Yes

**Are new data available? (Please do not repeat data that was reported in a prior year):** Yes

**Data measurement tool / source:** National programme data

**Other measurement tool / source:** HMIS

**From date:** 01/01/2014

**To date:** 31/12/2014

**Additional information related to entered data. e.g. reference to primary data source, methodological concerns::**

**Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::** Syphilis test is unknown - SD 3.0 Bioline

**Test type(s) generally used in your country to define positivity in pregnant women::** non-treponemal (RPR,VDRL),treponemal (rapid tests, TPPA),unknown

	All	<25	25+
<b>Percentage (%)</b> : Percentage of antenatal care attendees who were positive for syphilis	6.7		
<b>Numerator</b> : Number of antenatal care attendees who tested positive for syphilis	17987		
<b>Denominator</b> : Number of antenatal care attendees who were tested for syphilis	268845		

### 1.17.3 Percentage of antenatal care attendees positive for syphilis who received treatment

**is indicator/topic relevant?:** Yes

**Are new data available? (Please do not repeat data that was reported in a prior year):** No

**Data measurement tool / source:**

**Other measurement tool / source:**

**From date:**

**To date:**

**Additional information related to entered data. e.g. reference to primary data source, methodological concerns::**

**Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::**

**Are the data representative of the entire country?:** No

**If no, please describe:**

	Total
<b>Percentage (%)</b> : Percentage of antenatal care attendees positive for syphilis who received treatment	
<b>Numerator</b> : Number of antenatal care attendees with a positive syphilis serology who received at least one dose of benzathine penicillin 2.4 mU IM	
<b>Denominator</b> : Number of antenatal care attendees with a positive syphilis serology	

#### 1.17.4 Percentage of sex workers with active syphilis

**is indicator/topic relevant?:** Yes

**Are new data available? (Please do not repeat data that was reported in a prior year):** No

**Data measurement tool / source:**

**Other measurement tool / source:**

**From date:**

**To date:**

**Additional information related to entered data. e.g. reference to primary data source, methodological concerns::**

**Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::**

**Are the data representative of the entire country?:** No

**If no, please describe:**

**Are data consistent with the definition of active syphilis for GARPR (both treponemal and non-treponemal test positive)?:** No

**If no, please describe:**

	Total
<b>Percentage (%)</b> : Percentage of sex workers (SWs) with active syphilis	
<b>Numerator</b> : Number of sex workers who tested positive for active syphilis	
<b>Denominator</b> : Number of sex workers who were tested for syphilis	

#### 1.17.5 Percentage of men who have sex with men with active syphilis

**is indicator/topic relevant?:** Yes

**Are new data available? (Please do not repeat data that was reported in a prior year):** No

**Data measurement tool / source:**

**Other measurement tool / source:**

**From date:**

**To date:**

**Additional information related to entered data. e.g. reference to primary data source, methodological concerns::**  
**Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::**

**Are the data representative of the entire country?:** No

**If no, please describe:**

**Are data consistent with the definition of active syphilis for GARPR (both treponemal and non-treponemal test positive)?:** No

**If no, please describe:**

	Total
<b>Percentage (%) :</b> Percentage men who have sex with men (MSM) with active syphilis	
<b>Numerator :</b> Number of men who have sex with men who tested positive for active syphilis	
<b>Denominator :</b> Number of men who have sex with men who were tested for syphilis	

### 1.17.6 Number of adults reported with syphilis (primary/secondary and latent/unknown) in the past 12 months

**is indicator/topic relevant?:** Yes

**Are new data available? (Please do not repeat data that was reported in a prior year):** Yes

**Data measurement tool / source:** Other (please specify)

**Other measurement tool / source:** HMIS

**From date:** 01/01/2014

**To date:** 31/12/2014

**Additional information related to entered data. e.g. reference to primary data source, methodological concerns::**

**Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::**

**Are the data representative of the entire country?:** No

**If no, please describe:** Data is from Health Service delivery points which report through HMIS reported by health facilities with functional laboratory services.

	Total	Females	Males	Female (primary/secondary)	Male (primary/secondary)
<b>Numerator :</b> Number of adults reported with syphilis during the reporting period	75532				
<b>Denominator :</b> Number of individuals aged 15 and older	1000000				

### 1.17.7 Number of reported congenital syphilis cases (live births and stillbirths) in the past 12 months

**is indicator/topic relevant?:** Yes

**Are new data available? (Please do not repeat data that was reported in a prior year):** No

**Data measurement tool / source:**

**Other measurement tool / source:**

**From date:**

**To date:**

**Additional information related to entered data. e.g. reference to primary data source, methodological concerns::**  
**Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::**

**Are the data representative of the entire country?:** No

**If no, please describe:**

**Does your case definition for congenital syphilis include stillbirths?:**

	Total
<b>Numerator</b> : Number of reported congenital syphilis cases (live births and stillbirths) in the past 12 months	
<b>Denominator</b> : Number of live births	

### **1.17.8 Number of men reported with gonorrhoea in the past 12 months**

**is indicator/topic relevant?:** Yes

**Are new data available? (Please do not repeat data that was reported in a prior year):** No

**Data measurement tool / source:**

**Other measurement tool / source:**

**From date:**

**To date:**

**Additional information related to entered data. e.g. reference to primary data source, methodological concerns::**

**Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::**

**Are the data representative of the entire country?:** No

**If no, please describe:**

	Total
<b>Numerator</b> : Number of men reported with gonorrhoea in the past 12 months	
<b>Denominator</b> : Number of males aged 15 and older	

### **1.17.9 Number of men reported with urethral discharge in the past 12 months**

**is indicator/topic relevant?:** Yes

**Are new data available? (Please do not repeat data that was reported in a prior year):** Yes

**Data measurement tool / source:** Other (please specify)

**Other measurement tool / source:** HMIS

**From date:** 01/01/2014

**To date:** 31/12/2014

**Additional information related to entered data. e.g. reference to primary data source, methodological concerns::**

**Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::**

**Are the data representative of the entire country?:** Yes

**If no, please describe:**

	<b>Total</b>
<b>Numerator</b> : Number of men reported with urethral discharge in the past 12 months	72712
<b>Denominator</b> : Number of males aged 15 and older	1000000

### 1.17.10 Number of adults reported with genital ulcer disease in the past 12 months

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): Yes

Data measurement tool / source: Other (please specify)

Other measurement tool / source: HMIS

From date: 01/01/2014

To date: 31/12/2014

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::

Are the data representative of the entire country?: Yes

If no, please describe:

	Total	Males	Females
<b>Numerator</b> : Number of adults reported with genital ulcer disease during the reporting period	115613	42985	72628
<b>Denominator</b> : Number of individuals aged 15 and older	1000000	500000	500000

### 1.19 Diagnosis of HIV and AIDS cases

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): Yes

Data measurement tool / source: Other

Other measurement tool / source: HMIS

From date: 01/01/2014

To date: 31/12/2014

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::

#### Number of HIV cases diagnosed by sex from 2010-2014

	2014	2013	2012	2011	2010
<b>Both sexes</b>	339061				
<b>Males</b>	108281				
<b>Females</b>	230780				
<b>Sex unknown</b>	0				

#### Number of AIDS cases diagnosed by sex from 2010-2014

	2014	2013	2012	2011	2010
<b>Both sexes</b>					
<b>Males</b>					
<b>Females</b>					
<b>Sex unknown</b>					

### 1.22 Proportion of males circumcised

**is indicator/topic relevant?:** Yes

**Are new data available? (Please do not repeat data that was reported in a prior year):** No

**Data measurement tool / source:**

**Other measurement tool / source:**

**From date:**

**To date:**

**Additional information related to entered data. e.g. reference to primary data source, methodological concerns::**

The HMIS reporting system follows the Government of Uganda Financial Year July - June. The data in HMIS gets continuously updated for the entire FY. The reported data for SMC may change slightly by end of June 2015.

**Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::**

**Sample size - Number of Survey Respondents:**

	All (15-49)	15-19	20-24	25-49	Formal healthcare system	Traditional practitioner
<b>Percentage (%) :</b> Percentage of men 15-49 years that are circumcised						
<b>Numerator :</b> Number of male respondents aged 15-49 years who report that they are circumcised						
<b>Denominator :</b> Number of male respondents aged 15-49 years						

### 1.23 Number of male circumcisions performed

**is indicator/topic relevant?:** Yes

**Are new data available? (Please do not repeat data that was reported in a prior year):** Yes

**Data measurement tool / source:** Other

**Other measurement tool / source:** HMIS

**From date:** 01/01/2014

**To date:** 31/12/2014

**Additional information related to entered data. e.g. reference to primary data source, methodological concerns::**

The secondary tool for summarizing the SMC data (HMIS) has provisions for age ranges 1-<2yrs, 2-<5years, 5-<15, 15-49 and 50+. The numbers entered below have been approximated to the nearest age range..

**Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::**

**Sample size - Number of Survey Respondents:** 878109

	Total	< 1	1-9	10-14	15-19	20-24	25-49	15-49	50+
<b>Numerator :</b> Number of males circumcised during the past 12 months according to national standards	878109	7671	4480	276461				537270	52227

### B.3 People who inject drugs

**Case definition:** No study

**Number of sites:** 0

Information about the sites:

Sampling method:

Are the data representative of the entire country?: No

## 2.1 People who inject drugs: prevention programmes

is indicator/topic relevant?: No

Are new data available? (Please do not repeat data that was reported in a prior year): No

Data measurement tool / source:

Other measurement tool / source:

From date:

To date:

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::

	Total
Number of needles and syringes distributed per person who injects drugs per year by needle and syringe programmes	
<b>Numerator</b> : Number of needles and syringes distributed in past 12 months by NSPs	
<b>Denominator</b> : Number of people who inject drugs in the country	

## 2.2 People who inject drugs: condom use

is indicator/topic relevant?: No

Are new data available? (Please do not repeat data that was reported in a prior year): No

Data measurement tool / source:

Other measurement tool / source:

From date:

To date:

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::

Sample size - Number of Survey Respondents:

	All	Males	Females	<25	25+
<b>Percentage (%)</b> : Percentage of people who inject drugs reporting the use of a condom the last time they had sexual intercourse					
<b>Numerator</b> : Number of people who inject drugs who reported that a condom was used the last time they had sex					
<b>Denominator</b> : Number of people who inject drugs who report having injected drugs and having had sexual intercourse in the last month					

Total and disaggregated by age

Please enter the breakdown per site below. [Add as many as needed]

Site	Sample size	Percentage (%)	All - Numerator	All - Denominator	<25 - Numerator	<25 - Denominator	25+ - Numerator	25+ - Denominator
------	-------------	----------------	-----------------	-------------------	-----------------	-------------------	-----------------	-------------------

### Disaggregated by sex

Please enter the breakdown per site in the same order as in the table above. [Add as many as needed]

Site	Males - Numerator	Males - Denominator	Females - Numerator	Females - Denominator	Males (<25) - Numerator	Males (<25) - Denominator	Females (<25) - Numerator	Females (<25) - Denominator
------	-------------------	---------------------	---------------------	-----------------------	-------------------------	---------------------------	---------------------------	-----------------------------

## 2.3 People who inject drugs: safe injecting practices

is indicator/topic relevant?: No

Are new data available? (Please do not repeat data that was reported in a prior year): No

Data measurement tool / source:

Other measurement tool / source:

From date:

To date:

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::

Sample size - Number of Survey Respondents:

	All	Males	Females	<25	25+
<b>Percentage (%)</b> : Percentage of people who inject drugs reporting the use of sterile injecting equipment the last time they injected					
<b>Numerator</b> : Number of people who inject drugs who report using sterile injecting equipment the last time they injected drugs					
<b>Denominator</b> : Number of people who inject drugs who report injecting drugs in the last month					

### Total and disaggregated by age

Please enter the breakdown per site below. [Add as many as needed]

Site	Sample size	Percentage (%)	All - Numerator	All - Denominator	<25 - Numerator	<25 - Denominator	25+ - Numerator	25+ - Denominator
------	-------------	----------------	-----------------	-------------------	-----------------	-------------------	-----------------	-------------------

### Disaggregated by sex

Please enter the breakdown per site in the same order as in the table above. [Add as many as needed]

Site	Males - Numerator	Males - Denominator	Females - Numerator	Females - Denominator	Males (<25) - Numerator	Males (<25) - Denominator	Females (<25) - Numerator	Females (<25) - Denominator
------	-------------------	---------------------	---------------------	-----------------------	-------------------------	---------------------------	---------------------------	-----------------------------

## 2.4 HIV testing in people who inject drugs

is indicator/topic relevant?: No

Are new data available? (Please do not repeat data that was reported in a prior year): No

Data measurement tool / source:



**Other measurement tool / source:**

**From date:**

**To date:**

**Additional information related to entered data. e.g. reference to primary data source, methodological concerns::**

**Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::**

**Sample size - Number of Survey Respondents:**

	All	Males	Females	<25	25+
<b>Percentage (%) :</b> Percentage of people who inject drugs who received an HIV test in the past 12 months and know their results					
<b>Numerator :</b> Number of people who inject drugs respondents who have been tested for HIV during the last 12 months and who know their results					
<b>Denominator :</b> Number of people who inject drugs included in the sample					

**Total and disaggregated by age**

**Please enter the breakdown per site below. [Add as many as needed]**

Site	Sample size	Percentage (%)	All - Numerator	All - Denominator	<25 - Numerator	<25 - Denominator	25+ - Numerator	25+ - Denominator
------	-------------	----------------	-----------------	-------------------	-----------------	-------------------	-----------------	-------------------

**Disaggregated by sex**

**Please enter the breakdown per site in the same order as in the table above. [Add as many as needed]**

Site	Males - Numerator	Males - Denominator	Females - Numerator	Females - Denominator	Males (<25) - Numerator	Males (<25) - Denominator	Females (<25) - Numerator	Females (<25) - Denominator
------	-------------------	---------------------	---------------------	-----------------------	-------------------------	---------------------------	---------------------------	-----------------------------

## 2.5 HIV prevalence in people who inject drugs

**is indicator/topic relevant?:** Yes

**Are new data available? (Please do not repeat data that was reported in a prior year):** No

**Data measurement tool / source:**

**Other measurement tool / source:**

**From date:**

**To date:**

**Additional information related to entered data. e.g. reference to primary data source, methodological concerns::**

**Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::**

**Sample size - Number of Survey Respondents:**

	All	Males	Females	<25	25+
<b>Percentage (%) :</b> Percentage of people who inject drugs who are living with HIV					
<b>Numerator :</b> Number of people who inject drugs who test positive for HIV					
<b>Denominator :</b> Number of people who inject drugs tested for HIV					

### Total and disaggregated by age

Please enter the breakdown per site below. [Add as many as needed]

Site	Sample size	Percentage (%)	All - Numerator	All - Denominator	<25 - Numerator	<25 - Denominator	25+ - Numerator	25+ - Denominator
------	-------------	----------------	-----------------	-------------------	-----------------	-------------------	-----------------	-------------------

### Disaggregated by sex

Please enter the breakdown per site in the same order as in the table above. [Add as many as needed]

Site	Males - Numerator	Males - Denominator	Females - Numerator	Females - Denominator	Males (<25) - Numerator	Males (<25) - Denominator	Females (<25) - Numerator	Females (<25) - Denominator
------	-------------------	---------------------	---------------------	-----------------------	-------------------------	---------------------------	---------------------------	-----------------------------

## 2.6a Estimated number of opiate users (injectors and non-injectors)

is indicator/topic relevant?: No

Are new data available? (Please do not repeat data that was reported in a prior year): No

Data measurement tool / source:

Other measurement tool / source:

From date:

To date:

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::

Estimated number of opiate users (injectors and non-injectors), if available:

## 2.6b Number of people on opioid substitution therapy (OST)

is indicator/topic relevant?: No

Are new data available? (Please do not repeat data that was reported in a prior year): No

Data measurement tool / source:

Other measurement tool / source:

From date:

To date:

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::

Number of people on OST in all OST sites:

## 2.7a Number of needle and syringe programme sites

is indicator/topic relevant?: No

Are new data available? (Please do not repeat data that was reported in a prior year): No

Data measurement tool / source:

**Other measurement tool / source:**

**From date:**

**To date:**

**Additional information related to entered data. e.g. reference to primary data source, methodological concerns::**

**Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::**

**Number of NSP sites (including pharmacy sites providing no cost needles and syringes):**

## **2.7b Number of opioid substitution therapy (OST) sites**

**is indicator/topic relevant?:** No

**Are new data available? (Please do not repeat data that was reported in a prior year):** No

**Data measurement tool / source:**

**Other measurement tool / source:**

**From date:**

**To date:**

**Additional information related to entered data. e.g. reference to primary data source, methodological concerns::**

**Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::**

**Number of OST sites:**

## **3.1 Prevention of mother-to-child transmission**

**is indicator/topic relevant?:** Yes

**Are new data available? (Please do not repeat data that was reported in a prior year):** Yes

**Data measurement tool / source:** Numerator from ANC/PMTCT registers only

**Other measurement tool / source:** Data was generated from DHIS2

**From date:** 01/01/2014

**To date:** 31/12/2014

**Additional information related to entered data. e.g. reference to primary data source, methodological concerns::**

**Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::**

**The denominator for this indicator should come from your final Spectrum estimates file. The estimates file is not likely to be ready until late May. Please leave the denominator and percentage cells blank until you have the final value. The system will be reopened for updates to the denominators and percentage values for indicators 3.1, 3.1a, 3.2, 3.3 and 4.1 until 31 May.**

	Data value
<b>Percentage (%)</b> : Percentage of HIV-positive pregnant women who received antiretroviral medicine to reduce the risk of mother-to-child transmission	84
<b>Numerator</b> : Number of HIV-positive pregnant women who received antiretroviral drugs during the past 12 months to reduce the risk of mother-to-child transmission during pregnancy and delivery	112909
1. newly initiated on ART during the current pregnancy	50698
2. already on ART before the current pregnancy	61414
3. Maternal triple ARV prophylaxis (prophylaxis component of WHO Option B)	0
4. Maternal AZT (prophylaxis component during pregnancy and delivery of WHO Option A or WHO 2006 guidelines)	197
5. Single dose nevirapine (with or without tail) ONLY Please note that the final published value for PMTCT coverage will not include single dose nevirapine. However, this data is collected in the reporting tool during the phase out period.	0
6. Other (please comment: e.g. specify regimen, uncategorized, etc.) In the Comment Box, for the women reported as receiving an "Other" regimen, please describe the ARV regimen(s) and the number of women receiving each regimen category.	0
<b>If disaggregations 1 and 2 are not available, please provide the total number of pregnant women on Lifelong ART</b>	0
<b>Denominator</b> : Estimated number of HIV-positive pregnant women who delivered within the past 12 months	120000

**For the women reported as receiving an "Other" regimen, please describe the ARV regimen(s) and the number of women receiving each regimen category.:** There was no other regimen

### Sub-national data

**Please enter the breakdown per region below. [Add as many as needed]**

Sub-national region	Percentage (%)	Total number of HIV+ pregnant women who received ARV drugs	1. newly initiated on ART during the current pregnancy	2. already on ART before the current pregnancy	3. Maternal triple ARV prophylaxis (prophylaxis component of WHO Option B)	4. Maternal AZT (prophylaxis component during pregnancy and delivery of WHO Option A or WHO 2006 guidelines)	5. Single dose nevirapine (with or without tail) ONLY	6. Other	If disaggregations 1 and 2 are not available, please provide the total number of pregnant women on Lifelong ART	Denominator
Central 1		19069	8021	11006	0	42	0	0		
Central 2		13646	6652	6965	0	29	0	0		
East Central		5991	2818	3150	0	23	0	0		
Kampala		11044	4491	6464	0	89	0	0		
Mid Eastern		6518	3265	3207	0	46	0	0		
Mid Northern		16088	7511	8434	0	143	0	0		
Midwestern		14949	7237	7409	0	303	0	0		
North Eastern		5605	1998	3556	0	51	0	0		
South Western		16451	7097	9290	0	64	0	0		
West Nile		3549	1609	1934	0	6	0	0		

**Alternatively, you may [download this template](#), fill in the columns, and upload using the "Add File" button.**

### 3.1a Prevention of mother-to-child transmission during breastfeeding

**is indicator/topic relevant?:** Yes

**Are new data available? (Please do not repeat data that was reported in a prior year):** No

**Data measurement tool / source:**

**Other measurement tool / source:**

**From date:**

**To date:**

**Additional information related to entered data. e.g. reference to primary data source, methodological concerns::**

**Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::**

**The denominator for this indicator should come from your final Spectrum estimates file. The estimates file is not likely to be ready until late May. Please leave the denominator and percentage cells blank until you have the final value. The system will be reopened for updates to the denominators and percentage values for indicators 3.1, 3.1a, 3.2, 3.3 and 4.1 until 31 May.**

	Data value
<b>Percentage (%)</b> : Percentage of women living with HIV who are provided with antiretroviral medicines for themselves or their infants during the breastfeeding period	
<b>Numerator</b> : Number of women living with HIV who were breastfeeding who received antiretroviral medicine for herself or her child to reduce the risk of mother-to-child transmission during breastfeeding during the past 12 months.	
<b>Denominator</b> : Estimated number of women living with HIV who were breastfeeding in the past 12 months	

### 3.2 Early infant diagnosis

**is indicator/topic relevant?:** Yes

**Are new data available? (Please do not repeat data that was reported in a prior year):** Yes

**Data measurement tool / source:** EID Testing laboratories and sentinel surveillance

**Other measurement tool / source:**

**From date:** 01/01/2014

**To date:** 31/12/2014

**Additional information related to entered data. e.g. reference to primary data source, methodological concerns::**

**Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::**

**The denominator for this indicator should come from your final Spectrum estimates file. The estimates file is not likely to be ready until late May. Please leave the denominator and percentage cells blank until you have the final value. The system will be reopened for updates to the denominators and percentage values for indicators 3.1, 3.1a, 3.2, 3.3 and 4.1 until 31 May.**

	Data value
<b>Percentage (%)</b> : Percentage of infants born to HIV-positive women receiving a virological test for HIV within 2 months of birth	
<b>Numerator</b> : Number of infants who received an HIV test within two months of birth, during the reporting period. Infants tested should only be counted once	5359
<b>Test result - Positive</b>	208
<b>Test result - Negative</b>	5151
<b>Test result - Indeterminate</b>	0
<b>Test result - Rejected by laboratory</b>	0
<b>Test result - Other</b>	0
<b>Denominator</b> : Number of HIV-positive pregnant women giving birth in the last 12 months	

### 3.3 Mother-to-child transmission of HIV (modelled)

**is indicator/topic relevant?:** Yes

**Are new data available? (Please do not repeat data that was reported in a prior year):** Yes

**Data measurement tool / source:** Spectrum

**Other measurement tool / source:**

**From date:** 01/01/2015

**To date:** 31/12/2015

**Additional information related to entered data. e.g. reference to primary data source, methodological concerns::**

**Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::**

**This indicator should come from your final Spectrum estimates file. The estimates file is not likely to be ready until late May. Please leave the indicator blank until you have the final value. The system will be reopened for updates to this indicator until 31 May.**

	Data value
<b>Percentage (%)</b> : Estimated percentage of child HIV infections from HIV-positive women delivering in the past 12 months	4.6
<b>Numerator</b> : Estimated number of children who will be newly infected with HIV due to mother-to-child transmission among children born in the previous 12 months to HIV-positive women	5200
<b>Denominator</b> : Estimated number of HIV positive women who delivered in the previous 12 months	112309

### 3.3a Mother-to-child transmission of HIV (based on programme data)

**is indicator/topic relevant?:** Yes

**Are new data available? (Please do not repeat data that was reported in a prior year):** No

**Data measurement tool / source:**

**Other measurement tool / source:**

**From date:**

**To date:**

**Additional information related to entered data. e.g. reference to primary data source, methodological concerns::**

**Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::**

	Data value
<b>Percentage (%)</b> : Estimated percentage of child HIV infections from HIV-positive women delivering in the past 12 months	
<b>Numerator</b> : Number of children newly infected with HIV due to mother-to-child transmission among children born in the previous 12 months* to HIV-positive women * Or a different period for which you have data. Please specify on the additional information section.	
<b>Denominator</b> : Number of HIV positive women who delivered in the previous 12 months	

### 3.4 Percentage of pregnant women who know their HIV status (tested for HIV and received their results-during pregnancy, during labour and delivery, and during the post-partum period (<72 hours), including those with previously known HIV status

**is indicator/topic relevant?:** Yes

**Are new data available? (Please do not repeat data that was reported in a prior year):** Yes

**Data measurement tool / source:** Please specify

**Other measurement tool / source:** HMIS

**From date:** 01/01/2014

**To date:** 31/12/2014

**Additional information related to entered data. e.g. reference to primary data source, methodological concerns::**

**Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::**

**Percentage (%)**

	Data value
Percentage (%) - Percentage of pregnant women who were tested for HIV and received their results - during pregnancy, during labour and delivery, and during the post-partum period (<72 hours), including those with previously known HIV status	5

**Numerator - Number of pregnant women who were tested for HIV in the last 12 months and received their results - during pregnancy, during labour and delivery, and during the post-partum period (<72 hours), including those with previously known HIV status**

	Data value
Total number tested (including previously known positives)	1811647
Total number tested and received results (including previously known positives)	1811647
Total number testing positive (including previously known positives)	131495

**(a) Total number of pregnant women attending ANC who were tested during ANC and received results or knew their positive status.**

	Data value
Number tested (including previously known positives)	1493164
Number tested and received results (including previously known positives)	1493164
HIV+ out of number tested (including previously known positives)	122753

**(a.i) Number of pregnant women with unknown HIV status attending ANC who were tested during ANC and received results**

	Data value
Number tested	1408982
Number tested and received results	1408982
HIV+ out of number tested	51849

**(a.ii) Number of pregnant women with known HIV+ infection attending ANC for a new pregnancy**

	Data value
Number of HIV+ pregnant women	70904

**(b) Number of pregnant women with unknown HIV status attending L&D (labour and delivery) who were tested in L&D and received results**

	Data value
Number tested	186247
Number tested and received results	186247
HIV+ out of number tested	5841

**(c) Number of women with unknown HIV status attending postpartum services within 72 hours of delivery who were tested and received results**

	Data value
Number tested	132236
Number tested and received results	132236
HIV+ out of number tested	2901

**Denominator**

	Data value
Denominator - Estimated number of pregnant women	

### 3.5 Percentage of pregnant women attending antenatal care whose male partner was tested for HIV in the last 12 months

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): Yes

Data measurement tool / source: Please specify

Other measurement tool / source: HMIS

From date: 01/01/2014

To date: 31/12/2014

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::

	Data value
<b>Percentage (%)</b> : Percentage of pregnant women attending antenatal care whose male partner was tested for HIV in the last 12 months	23.5
<b>Numerator</b> : Number of pregnant women attending antenatal care whose male partner was tested in the last 12 months	366272
<b>Denominator</b> : Number of pregnant women attending antenatal care	1561477

### 3.6 Percentage of HIV-infected pregnant women assessed for ART eligibility through either clinical staging or CD4 testing

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): Yes

Data measurement tool / source: Please specify

Other measurement tool / source: HMIS

From date: 01/01/2014

To date: 31/12/2014

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::

	Data value
<b>Percentage (%)</b> : Percentage of HIV-infected pregnant women assessed for ART eligibility through either clinical staging or CD4 testing	85
<b>Numerator</b> : Number of HIV-infected pregnant women assessed for ART eligibility	53580
<b>Disaggregation by method of assessment</b> : Clinical staging only	36631
<b>Disaggregation by method of assessment</b> : CD4 testing Women who were assessed both by CD4 testing and by clinical staging should be counted only once, as having been assessed by CD4 testing.	16949
<b>Denominator</b> : Estimated number of HIV-infected pregnant women	170000

### 3.7 Percentage of infants born to HIV-infected women provided with antiretroviral prophylaxis to reduce the risk of early mother-to-child transmission in the first 6 weeks

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): Yes

Data measurement tool / source: Please specify

Other measurement tool / source: HMIS

From date: 01/01/2014

To date: 31/12/2014

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::



**Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::**

	Data value
<b>Percentage (%)</b> : Percentage of infants born to HIV-infected women (HIV-exposed infants) who received antiretroviral prophylaxis to reduce the risk of early mother-to-child- transmission in the first 6 weeks (i.e. early postpartum transmission around 6 weeks of age) <b>Note. Ideally countries should capture the percentage of infants who received ARV prophylaxis. If this is not possible then countries should record the percentage of infants who were started on or provided with ARV prophylaxis.</b>	25
<b>Numerator</b> : Number of infants born to HIV-infected women who received antiretroviral prophylaxis to reduce early mother-to-child transmission (early postpartum, in the first 6 weeks)	41356
<b>Denominator</b> : Estimated number of HIV-infected pregnant women giving birth	120112

### 3.9 Percentage of infants born to HIV-infected women started on cotrimoxazole (CTX) prophylaxis within two months of birth

**is indicator/topic relevant?:** Yes

**Are new data available? (Please do not repeat data that was reported in a prior year):** Yes

**Data measurement tool / source:** Please specify

**Other measurement tool / source:** HMIS

**From date:** 01/01/2014

**To date:** 31/12/2014

**Additional information related to entered data. e.g. reference to primary data source, methodological concerns::**

**Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::**

	Data value
<b>Percentage (%)</b> : Percentage of infants born to HIV-infected women started on cotrimoxazole (CTX) prophylaxis within two months of birth	35.8
<b>Numerator</b> : Number of infants born to HIV-infected women started on CTX prophylaxis within two months of birth	43052
<b>Denominator</b> : Estimated number of HIV-infected pregnant women giving birth	120112

### 3.10 Distribution of Outcomes of HIV-Exposed Infants

**is indicator/topic relevant?:** Yes

**Are new data available? (Please do not repeat data that was reported in a prior year):** No

**Data measurement tool / source:**

**Other measurement tool / source:**

**From date:**

**To date:**

**Additional information related to entered data. e.g. reference to primary data source, methodological concerns::**

**Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::**

**3.10.1 Number of infants born to HIV positive mothers (“HIV-exposed infants”) born in 2013 (or latest data available):**

**Reporting year (2013 or earlier):**

**3.10.2 Number of infants, born in 2013 (or latest data available) to HIV positive mothers, classified as indeterminate (i.e.: all lost to follow up, death before definitive diagnosis, indeterminate lab results):**

**Reporting year (2013 or earlier):**

**3.10.3 Number of infants born in 2013 (or latest data available) to HIV positive mothers that are diagnosed as positive for HIV:**

**Reporting year (2013 or earlier):**

**3.10.4 Number of infants born to HIV positive mothers in 2013 (or latest data available) that are diagnosed as negative for HIV:**

**Reporting year (2013 or earlier):**

### **3.11 Number of pregnant women attending ANC at least once during the reporting period**

**is indicator/topic relevant?:** No

**Are new data available? (Please do not repeat data that was reported in a prior year):** No

**Data measurement tool / source:**

**Other measurement tool / source:**

**From date:**

**To date:**

**Additional information related to entered data. e.g. reference to primary data source, methodological concerns::**

**Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::**

**Number of pregnant women attending ANC at least once during the reporting period:**

**Are the data representative of the entire country?:** No

**If no, please describe:**

### **4.1 HIV treatment: antiretroviral therapy**

**is indicator/topic relevant?:** Yes

**Are new data available? (Please do not repeat data that was reported in a prior year):** Yes

**Data measurement tool / source:** Other tools (please define data sources for numerator and denominator below)

**Other measurement tool / source:** The denominator data is from spectrum estimates of 2014 while the numerator data is from the HMIS

**From date:** 01/01/2014

**To date:** 31/12/2014

**Additional information related to entered data. e.g. reference to primary data source, methodological concerns::**

**Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::**

**The denominator for this indicator should come from your final Spectrum estimates file. The estimates file is not likely to be ready until late May. Please leave the denominator and percentage cells blank until you have the final value. The system will be reopened for updates to the denominators and percentage values for indicators 3.1, 3.1a, 3.2, 3.3 and 4.1 until 31 May.**

**Total and disaggregated by sex**

	Total	Males	Females	Gender unknown
<b>Percentage (%)</b> : Percentage of adults and children currently receiving antiretroviral therapy among all adults and children living with HIV	50.1	42	56	0
<b>Numerator</b> : Number of adults and children currently receiving antiretroviral therapy in accordance with the nationally approved treatment protocol (or WHO standards) at the end of the reporting period.	750896	256600	494296	0
<b>Denominator</b> : Estimated number of adults and children living with HIV <b>National criteria for ART eligibility varies by country. To make this indicator comparable across countries global reports will present the ART coverage for adults and children as a percent of all people living with HIV.</b>	1500000	611538	888462	0
<b>Denominator</b> : Estimated number of eligible adults and children (using national eligibility criteria)				
<b>Number</b> : Persons newly initiating antiretroviral therapy during the last reporting year	125744	42970	82774	0

### Disaggregated by broad age group

	<15	15+	Age unknown
<b>Percentage (%)</b> : Percentage of adults and children currently receiving antiretroviral therapy among all adults and children living with HIV <b>Percentage is based on Denominator 1.</b>	28.1	53.4	0
<b>Numerator</b> : Number of adults and children currently receiving antiretroviral therapy in accordance with the nationally approved treatment protocol (or WHO standards) at the end of the reporting period.	56296	694627	0
<b>Denominator 1</b> : Estimated number of adults and children living with HIV	200000	1300000	0
<b>Denominator 2</b> : Estimated number of eligible adults and children (using national eligibility criteria) <b>National criteria for ART eligibility varies by country. To make this indicator comparable across countries, global reports will present the ART coverage for adults and children as a percent of all people living with HIV.</b>			
<b>Number</b> : Persons newly initiating antiretroviral therapy during the last reporting year	11199	114545	0

### Disaggregated by detailed age group

	< 1	1-4	5-9	10-14	15-19	20-24	25-49	50+
<b>Percentage (%)</b> : Percentage of adults and children currently receiving antiretroviral therapy among all adults and children living with HIV <b>Percentage is based on Denominator 1.</b>								
<b>Numerator :</b> Number of adults and children currently receiving antiretroviral therapy in accordance with the nationally approved treatment protocol (or WHO standards) at the end of the reporting period.				56296	694627			
<b>Denominator 1 :</b> Estimated number of adults and children living with HIV				200000	1300000			
<b>Denominator 2 :</b> Estimated number of eligible adults and children (using national eligibility criteria) <b>National criteria for ART eligibility varies by country. To make this indicator comparable across countries, global reports will present the ART coverage for adults and children as a percent of all people living with HIV.</b>								
<b>Number :</b> Persons newly initiating antiretroviral therapy during the last reporting year				11199	114545			

### Disaggregated by sector

	Public sector	Private sector
<b>Numerator :</b> Number of adults and children currently receiving antiretroviral therapy in accordance with the nationally approved treatment protocol (or WHO standards) at the end of the reporting period.		

### Sub-national data

Please enter the breakdown per region below. [Add as many as needed]

Sub-national region	All ages - Percentage	All ages - Numerator	All ages - Denominator 1	Children (<15) - Percentage	Children (<15) - Numerator	Children (<15) - Denominator 1	Adults (15+) - Percentage	Adults (15+) - Numerator	Adults (15+) - Denominator 1
Central 1		123357			9365			113992	
Central 2		79257			5534			73723	
East Central		48384			3661			44723	
Kampala		113143			7849			105294	
Mid Eastern		45245			3817			41428	
Mid Northern		94139			7834			86305	
Mid Western		80630			6128			74502	
North Eastern		36542			3457			33085	
South Western		105047			6736			98311	
West Nile		25152			1888			23264	

Alternatively, you may [download this template](#), fill in the columns, and upload using the "Add File" button.

#### 4.2a HIV Treatment: 12 months retention

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): Yes

Data measurement tool / source: Other tools (please specify)

Other measurement tool / source: HMIS

From date: 01/01/2014

To date: 30/09/2014

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::

Sample size - Number of Survey Respondents: 680000

	Total	Males	Females	<15	15+	Pregnancy status at start of therapy	Breastfeeding status at start of therapy
<b>Percentage (%) :</b> Percentage of adults and children with HIV known to be on treatment 12 months after initiating treatment among patients initiating antiretroviral therapy	84.9	84.9	84.9	88.1	84.7		
<b>Numerator :</b> Number of adults and children who are still alive and on antiretroviral therapy at 12 months after initiating treatment	54012	16329	37683	3259	50753		
<b>Denominator :</b> Total number of adults and children who initiated antiretroviral therapy who were expected to achieve 12-month outcomes within the reporting period including those who have died since starting antiretroviral therapy, those who have stopped antiretroviral therapy, and those recorded as lost to follow-up at month 12	63618	19233	44385	3698	59920		

**Additional info: In addition to 'alive and on ART', please report other outcomes at 12 months after initiating treatment**

**Lost to follow-up:**

**Stopped Therapy:**

**Died:**

#### **4.2b HIV Treatment: 24 months retention**

**is indicator/topic relevant?:** Yes

**Are new data available? (Please do not repeat data that was reported in a prior year):** No

**Data measurement tool / source:**

**Other measurement tool / source:**

**From date:**

**To date:**

**Additional information related to entered data. e.g. reference to primary data source, methodological concerns::**

**Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::**

**Sample size - Number of Survey Respondents:**

	Total	Males	Females	<15	15+	Pregnancy status at start of therapy	Breastfeeding status at start of therapy
<p><b>Percentage (%) :</b> Percentage of adults and children with HIV known to be on treatment 24 months after initiating treatment among patients initiating antiretroviral therapy during 2012. If data on 24-month retention are not available for patients that initiated antiretroviral therapy in 2012, but available for patients that initiated antiretroviral therapy during an earlier time period (e.g. 2011), please specify the period in the comment field: e.g. "Started antiretroviral therapy between [month]/[year] and [month]/[year]".</p>							
<p><b>Numerator :</b> Number of adults and children who are still alive and on antiretroviral therapy at 24 months after initiating treatment (among those who initiated ART in 2012)</p>							
<p><b>Denominator :</b> Total number of adults and children who initiated ART in 2012 (or another specified period), who were expected to achieve 24-month outcomes within the 2014 reporting period (or 24 months after the specified initiation period), including those who have died since starting ART, those who have stopped ART, and those recorded as lost to follow-up at month 24 including those who have died since starting antiretroviral therapy, those who have stopped antiretroviral therapy, and those recorded as lost to follow-up at month 24</p>							

**Additional info: In addition to 'alive and on ART', please report other outcomes at 24 months after initiating treatment**

**Lost to follow-up:**

**Stopped Therapy:**

**Died:**

#### **4.2c HIV Treatment: 60 months retention**

**is indicator/topic relevant?:** Yes

**Are new data available? (Please do not repeat data that was reported in a prior year):** No

**Data measurement tool / source:**

**Other measurement tool / source:**

**From date:**

**To date:**

**Additional information related to entered data. e.g. reference to primary data source, methodological concerns::**

**Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::** No data

**Sample size - Number of Survey Respondents:**



	Total	Males	Females	<15	15+	Pregnancy status at start of therapy	Breastfeeding status at start of therapy
<p><b>Percentage (%) :</b> Percentage of adults and children with HIV known to be on treatment 60 months after initiating treatment among patients initiating antiretroviral therapy during 2009. If data on 60-month retention are not available for patients that initiated antiretroviral therapy in 2009, but available for patients that initiated antiretroviral therapy during an earlier time period (e.g. 2008), please specify the period in the comment field above: Started antiretroviral therapy between [month]/[year] and [month]/[year]</p>							
<p><b>Numerator :</b> Number of adults and children who are still alive and on antiretroviral therapy at 60 months after initiating treatment (among those who initiated ART in 2009)</p>							
<p><b>Denominator :</b> Total number of adults and children who initiated antiretroviral therapy in 2009 who were expected to achieve 60-month outcomes within the 2014 reporting period including those who have died since starting antiretroviral therapy, those who have stopped antiretroviral therapy, and those recorded as lost to follow-up at month 60</p>							

**Additional info: In addition to 'alive and on ART', please report other outcomes at 60 months after initiating treatment**

**Lost to follow-up:**

**Stopped Therapy:**

**Died:**

#### **4.3a Health facilities that offer antiretroviral therapy**

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): Yes

Data measurement tool / source: Please specify

Other measurement tool / source: HMIS

From date: 01/01/2014

To date: 30/06/2014

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::

	Total
Total number of health facilities that offer antiretroviral therapy (ART) (i.e. prescribe and/or provide clinical follow-up)	1603

#### Disaggregation by public/private:

	Data value
Public	
Private	
Unknown/unspecified	

#### Disaggregation by health centre type:

	Data value
Hospital	125
Health centre	1415
ANC	
TB service	
STI	
Unknown/unspecified	

### 4.3b Health facilities that offer paediatric antiretroviral therapy

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): Yes

Data measurement tool / source: Please specify

Other measurement tool / source: HMIS

From date: 01/01/2014

To date: 30/06/2014

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::

	Total
Total number of health facilities that offer paediatric antiretroviral therapy (ART) (i.e. prescribe and/or provide clinical follow-up)	1062

#### Disaggregation by public/private:

	Data value
Public	
Private	
Unknown/unspecified	

### 4.4 ART stockouts

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): Yes

**Data measurement tool / source:** Please specify

**Other measurement tool / source:** HMIS

**From date:** 01/01/2014

**To date:** 31/12/2014

**Additional information related to entered data. e.g. reference to primary data source, methodological concerns::**

**Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::**

	Data value
<b>Percentage (%)</b> : Percentage of health facilities dispensing ARVs that experienced a stock-out of at least one required ARV drug in the last 12 months	47.9
<b>Numerator</b> : Number of health facilities dispensing ARVs that experienced a stock-out of one or more required ARV drug in the last 12 months	768
<b>Denominator</b> : Total number of health facilities dispensing ARVs	1603

**In case of stockout, please list the ARV formulations which were out of stock. What was done to prevent treatment interruption for patients who were taking these formulations? :**

## 4.5 Percentage of HIV positive persons with first CD4 cell count < 200 cells/ $\mu$ L in 2014

**is indicator/topic relevant?:** Yes

**Are new data available? (Please do not repeat data that was reported in a prior year):** Yes

**Data measurement tool / source:** Please specify

**Other measurement tool / source:** January-June 2014 ART national report

**From date:** 01/01/2014

**To date:** 30/06/2014

**Additional information related to entered data. e.g. reference to primary data source, methodological concerns::**

**Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::** The indicator is relevant, though redefined to track those below 250 and at the start of ART

	Data value
<b>Percentage (%)</b> : Percentage of HIV positive persons with first CD4 cell count < 200 cells/ $\mu$ L in 2014	47
<b>Numerator</b> : Number of HIV-positive people with first CD4 cell count <200 cells/ $\mu$ L in 2014	47
<b>Denominator</b> : Total number of HIV-positive people with first CD4 cell count in 2014	100

## 4.6 HIV Care

**is indicator/topic relevant?:** Yes

**Are new data available? (Please do not repeat data that was reported in a prior year):** Yes

**Data measurement tool / source:** Please specify

**Other measurement tool / source:**

**From date:** 01/01/2014

**To date:** 31/12/2014

**Additional information related to entered data. e.g. reference to primary data source, methodological concerns::**

**Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::**

	Total	Males	Females	Gender unknown	<15	15+	Age unknown
<b>4.6.a Total number of adults and children enrolled in HIV care at the end of the reporting period</b>	930793	320421	610372	0	64345	866448	
<b>4.6.b Number of adults and children newly enrolled in HIV care during the reporting period</b>	245600	88531	157069	0	14743	230857	

#### 4.7a Percentage of people on ART tested for viral load (VL) who were virally suppressed in the reporting period

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): Yes

Data measurement tool / source: Other

Other measurement tool / source: ART Report 2014

From date: 01/01/2014

To date: 31/12/2014

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::

	Total	Males	Females	Gender unknown	<15	15+	Age unknown
<b>Percentage (%) :</b> Percentage of people on ART tested for viral load who were virally suppressed in the reporting period	85						
<b>Numerator :</b> Number of people on ART tested for viral load in the reporting period with suppressed viral load (i.e. $\leq$ 1000 copies/ml)							
<b>Denominator :</b> Number of people on ART tested for viral load in the reporting period							

#### 4.7b Percentage of people on ART tested for viral load (VL) with VL level $\leq$ 1000 copies/ml after 12 months of therapy

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): Yes

Data measurement tool / source: Please specify

Other measurement tool / source: ART 2014 Report

From date: 01/01/2014

To date: 31/12/2014

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::

	Total	Males	Females	Gender unknown	<15	15+	Age unknown
<b>Percentage (%) :</b> Percentage of people on ART tested for viral load (VL) with VL level $\leq$ 1000 copies/ml after 12 months of therapy	88						
<b>Numerator :</b> Number of people tested after 12 months therapy for VL and have suppression ( VL $\leq$ 1000 copies/ml ) during the reporting period							
<b>Denominator :</b> Number of people tested after 12 months therapy for VL during the reporting period							

#### 4.7c Percentage of people on ART tested for viral load (VL) with undetectable viral load in the reporting period

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): No

Data measurement tool / source:

Other measurement tool / source:

From date:

To date:

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source:: Data not being captured.

	Total	Males	Females	Gender unknown	<15	15+	Age unknown
<b>Percentage (%) :</b> Percentage of people on ART tested for viral load (VL) with undetectable viral load in the reporting period							
<b>Numerator :</b> Number of people on ART tested for viral load in the reporting period with undetectable viral load (i.e. $\leq$ 50 copies)							
<b>Denominator :</b> Number of people on ART tested for viral load in the reporting period							

#### 5.1 Co-management of tuberculosis and HIV treatment

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): Yes

Data measurement tool / source: Other tools (please define data sources for numerator and denominator below)

Other measurement tool / source: HMIS

From date: 01/01/2014

**To date:** 31/12/2014

**Additional information related to entered data. e.g. reference to primary data source, methodological concerns::**

Data for 2 quarters

**Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::**

	Total	Males	Females	<15	15+
<b>Numerator</b> : Number of people with HIV infection who received antiretroviral combination therapy in accordance with the nationally approved treatment protocol (or WHO/UNAIDS standards) and who were started on TB treatment (in accordance with national TB programme guidelines), within the reporting year	15877				

**Note: Estimates of HIV-positive incident TB cases will be available at the end of July, based on data provided by countries. Should you wish to see the estimates for last year to get an idea of the coverage, please go to [WHO TB Data Download page](#)**

## **5.2 Percentage of adults and children living with HIV newly enrolled in care who are detected having active TB disease**

**is indicator/topic relevant?:** Yes

**Are new data available? (Please do not repeat data that was reported in a prior year):** Yes

**Data measurement tool / source:** Please specify

**Other measurement tool / source:** HMIS

**From date:** 01/01/2014

**To date:** 31/12/2014

**Additional information related to entered data. e.g. reference to primary data source, methodological concerns::**

**Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::**

	Total	Males	Females	Gender unknown	<15	15+	Age unknown
<b>Percentage (%) :</b> Percentage of adults and children newly enrolled in HIV care who are detected having active TB disease	2	2	2	2	2	2	2
<b>Numerator :</b> Total number of adults and children newly enrolled in HIV care who are diagnosed as having active TB disease during the reporting period	100	100	100	100	100	100	100
<b>Denominator :</b> Total number of adults and children newly enrolled in pre-ART care or on ART during the reporting period <b>This denominator should be the same as the denominator of indicator 5.3</b>	60578	22154	38424	0	3790	56788	0

### 5.3 Percentage of adults and children newly enrolled in HIV care starting isoniazid preventive therapy (IPT)

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): No

Data measurement tool / source:

Other measurement tool / source:

From date:

To date:

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::

	Data value
<b>Percentage (%) :</b> Percentage of adults and children newly enrolled in HIV care starting isoniazid preventive therapy (IPT)	
<b>Numerator :</b> Number of adults and children newly enrolled (i.e. started) in HIV care (pre-ART and ART) who also start (i.e. given at least one dose) isoniazid preventive therapy treatment during the reporting period <b>HIV care includes pre-ART and ART.</b>	
<b>Denominator :</b> Number of adults and children newly enrolled (i.e. started) in HIV care during the reporting period. <b>This denominator should be the same as the denominator of indicator 5.2</b>	

### 5.4 Percentage of adults and children enrolled in HIV care who had their TB status assessed and recorded during their last visit

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): Yes

Data measurement tool / source: Please specify

Other measurement tool / source: HMIS

From date: 01/01/2014

To date: 31/12/2014

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::

	Data value
<b>Percentage (%)</b> : Percentage of adults and children enrolled in HIV care who had TB status assessed and recorded during their last visit	78.3
<b>Numerator</b> : Number of adults and children in HIV care, who had their TB status assessed and recorded during their last visit <b>HIV care includes pre-ART and ART.</b>	729268
<b>Denominator</b> : Total number of adults and children in HIV care in the reporting period	930793

## 6.1 AIDS spending

**is indicator/topic relevant?:** Yes

**Are new data available? (Please do not repeat data that was reported in a prior year):** No

**Data measurement tool / source:**

**Other measurement tool / source:**

**From date:**

**To date:**

**Additional information related to entered data. e.g. reference to primary data source, methodological concerns::**

**Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::**

**Download an empty National Funding Matrix, [GARPR-6-1 en.xlsx](#)**

**Then, upload the filled-in form using the "Add file" button.**

### Reporting years

**Please enter the reporting years below in reverse chronological order. [Add as many as needed]**

Reporting Start Date	Reporting End Date
----------------------	--------------------

## 7.1 Prevalence of recent intimate partner violence

**is indicator/topic relevant?:** Yes

**Are new data available? (Please do not repeat data that was reported in a prior year):** No

**Data measurement tool / source:**

**Other measurement tool / source:**

**From date:**

**To date:**

**Additional information related to entered data. e.g. reference to primary data source, methodological concerns::**

**Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::**

**Sample size - Number of Survey Respondents:**



	Females (all ages)	HIV+ Females	HIV- Females	Females with unknown HIV status	Females (15-19)	HIV+ Females (15-19)	HIV- Females (15-19)	Females with unknown HIV status (15-19)	Females (20-24)	HIV+ Females (20-24)	HIV- Females (20-24)	Females with unknown HIV status (20-24)	Females (25-49)	HIV+ Females (25-49)	HIV- Females (25-49)	Females with unknown HIV status (25-49)
<b>Percentage (%) :</b> Proportion of ever-married or partnered women aged 15-49 who experienced physical or sexual violence from a male intimate partner in the past 12 months																
<b>Numerator :</b> Women aged 15-49 who currently have or ever had an intimate partner, who report experiencing physical or sexual violence by at least one of these partners in the past 12 months																
<b>Denominator :</b> Total women surveyed aged 15-49 who currently have or had an intimate partner																

If data is available on gender-based violence towards key populations, kindly include this data in the comment box below. Please upload any relevant reports using the "Add File" button at the top of this page.:

## 8.1 Discriminatory attitudes towards people living with HIV

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): No

Data measurement tool / source:

Other measurement tool / source:

From date:

To date:

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::

This indicator was included in GARPR for the first time during the 2014 reporting round. As this indicator is relatively new, it is likely that many countries will not be able to report on the indicator during the 2015 reporting round. Instead, countries are requested to report data from the previous version of question 1, 'Would you buy fresh vegetables from a shopkeeper or vendor if you knew that this person had the AIDS virus?'. This question has been routinely collected in DHS in many countries. In future reporting rounds, countries should report on the full indicator.

Sample size - Number of Survey Respondents:

Answered "No" to question 1 "Would you buy fresh vegetables from a shopkeeper or vendor if you knew that this person had HIV?"

	All ages	Males (all ages)	Males (15-19)	Males (20-24)	Males (25-49)	Females (all ages)	Females (15-19)	Females (20-24)	Females (25-49)
<b>Percentage (%) :</b> Percentage of respondents (aged 15-49 years) who respond "No" to question 1									
<b>Numerator :</b> Number of respondents (aged 15-49 years) who respond "No" to question 1									
<b>Denominator :</b> Number of all respondents aged 15-49 years who have heard of HIV									
<b>Responded "Don't know", "Not Sure", or "It depends" :</b> Number of all respondents aged 15-49 years who responded "don't know", "not sure", or "it depends" to question 1									

**Data measurement tool/source for Question 2:**

**If data measurement tool/source for Question 2 is "Other", please specify:**

**Answered "No" to question 2 "Do you think children living with HIV should be able to attend school with children who are HIV negative?"**

	All ages	Males (all ages)	Males (15-19)	Males (20-24)	Males (25-49)	Females (all ages)	Females (15-19)	Females (20-24)	Females (25-49)
<b>Percentage (%) :</b> Percentage of respondents (aged 15-49 years) who respond "No" to question 2									
<b>Numerator :</b> Number of respondents (aged 15-49 years) who respond "No" to question 2									
<b>Denominator :</b> Number of all respondents aged 15-49 years who have heard of HIV									
<b>Responded "Don't know", "Not Sure", or "It depends" :</b> Number of all respondents aged 15-49 years who responded "don't know", "not sure", or "it depends" to question 2									

### Answered "No" to both questions

	All ages	Males (all ages)	Males (15-19)	Males (20-24)	Males (25-49)	Females (all ages)	Females (15-19)	Females (20-24)	Females (25-49)
<b>Percentage (%) :</b> Percentage of respondents (aged 15-49 years) who respond "No" to both of the two questions									
<b>Numerator :</b> Number of respondents (aged 15-49 years) who respond "No" to both of the two questions									
<b>Denominator :</b> Number of all respondents aged 15-49 years who have heard of HIV									

### 10.1 Orphans school attendance

**is indicator/topic relevant?:** Yes

**Are new data available? (Please do not repeat data that was reported in a prior year):** No

**Data measurement tool / source:**

**Other measurement tool / source:**

**From date:**

**To date:**

**Additional information related to entered data. e.g. reference to primary data source, methodological concerns::**

**Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::**

### PART A

	All	Males	Females
<b>Percentage (%)</b> : Current school attendance rate of orphans aged 10-14 primary school age, secondary school age			
<b>Numerator</b> : Number of children who have lost both parents and who attend school aged 10-14, primary school age, secondary school age			
<b>Denominator</b> : Number of children who have lost both parents			

### PART B

	All	Males	Females
<b>Percentage (%)</b> : Current school attendance rate of children aged 10-14 primary school age, secondary school age both of whose parents are alive and who live with at least one parent			
<b>Numerator</b> : Number of children both of whose parents are alive, who are living with at least one parent and who attend school aged 10-14, primary school age, secondary school age			
<b>Denominator</b> : Number of children both of whose parents are alive who are living with at least one parent			

## 10.2 External economic support to the poorest households

**is indicator/topic relevant?:** Yes

**Are new data available? (Please do not repeat data that was reported in a prior year):** No

**Data measurement tool / source:**

**Other measurement tool / source:**

**From date:**

**To date:**

**Additional information related to entered data. e.g. reference to primary data source, methodological concerns::**

**Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::**

	Data value
<b>Percentage (%)</b> : Proportion of the poorest households who received external economic support in the last 3 months	
<b>Numerator</b> : Number of the poorest households that received any form of external economic support in the last 3 months <b>External economic support is defined as free economic help (cash grants, assistance for school fees, material support for education, income generation support in cash or kind, food assistance provided at the household level, or material or financial support for shelter) that comes from a source other than friends, family or neighbours unless they are working for a community-based group or organization. This source is most likely to be the national government or a civil society organization.</b>	
<b>Denominator</b> : Total number of poorest households <b>Poorest households are defined as a household in the bottom wealth quintile. Countries should use the exact indicator definition and method of measurement for standardized progress monitoring and reporting at national and global levels. This will allow monitoring of changes over time and comparisons across different countries. However, countries can add or exclude other categories locally (for example, other wealth quintiles) depending on the country needs with respect to national programme planning and implementation</b>	

### P.1b Policy and Programmatic Questions

**is indicator/topic relevant?:** Yes

**Are new data available? (Please do not repeat data that was reported in a prior year):** No

**Data measurement tool / source:**

**Other measurement tool / source:**

**From date:**

**To date:**

**Additional information related to entered data. e.g. reference to primary data source, methodological concerns::**

**Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::**

## **A HIV testing and counselling**

**For each set of questions, please indicate: yes, no, don't know.**

### **1) Populations. Does the current HTC guidelines address :**

**Children:** Yes

**Adolescents:** Yes

**Key populations:** Yes

### **2) PITC. Does the current HTC guidelines recommend PITC for:**

**all medical contacts :** Yes

**all pregnant women:** Yes

**all paediatric patients:** Yes

**all people in TB clinics:** Yes

**all people in STI clinics:** Yes

**all people in Hepatitis services:** Yes

**all key populations attending key population-specific clinical services:** Yes

**other populations:** Yes

**please specify::** HCT is for everybody in the country

### **3) Community-based testing. Does the current HTC guidelines recommend:**

**community based HTC:** Yes

**use of rapid tests :** Yes

**rapid tests for same day results:** Yes

**rapid tests to be performed by lay providers:** No

### **4) Couples/partner HTC. Does the current HTC guidelines recommend:**

Couples/partner HTC in all settings: Yes

Couples/partner HTC in PMTCT programmes: Yes

## B Antiretroviral Therapy

### 1) What is the status of ARV guidelines?

Adult ART guidelines: [u'December, 2013', u'Consolidated']

PMTCT guidelines: [u'December, 2013', u'Consolidated']

Paediatric ART guidelines: [u'December, 2013', u'Consolidated']

Operational guidelines:

### 2) Have recommendations of the WHO 2013 Guidelines on the use of ARVs for the Prevention and Treatment of HIV been adapted in a national process?

a) Adult ART guidelines:: Yes, completed

Please provide a comment if you choose "Other":

b) PMTCT guidelines:: Yes, completed

Please provide a comment if you choose "Other":

c) Paediatric ART guidelines:: Yes, completed

Please provide a comment if you choose "Other":

### 3) What are the national ART targets:

	Number	Year
1	1257477	2014
2		

b) Among pregnant women, what are the targets for: PMTCT ART coverage target\* (e.g. XX % by 2015):

	Percentage	Year
1	126799	2014
2		

### 4) What is the recommended CD4 threshold for initiating ART in adults and adolescents who are asymptomatic?

a) (as per MOH guidelines or directive)?: all regardless of CD4 count (test and treat)

If "Other", please specify:

b) What is the implementation and practice of initiating ART at a CD4 threshold of 500 among adults and adolescents?: Done country-wide

**Please provide a comment if you choose "Other":**

**c) What is the implementation and practice of initiating ART regardless of CD4 count among adults and adolescents?:** Done in a large number of treatment sites

**Please provide a comment if you choose "Other":**

**5) If national guidelines recommend a CD4 threshold of 500, is there prioritization given to persons with a CD4  $\leq$  350 or to those with advanced clinical disease?:** Yes

**If yes, please specify:**

**Please provide a comment if you choose "Other":**

**6) What are the ART initiation criteria adopted in national guidelines for infants and children with HIV?**

**a) Age cut-off to treat all children irrespective of symptoms as per MOH guidelines or directive::** < 15 years

**Please provide a comment if you choose "Other":**

**b) What is the implementation status of the policy adopted above?:** Done country-wide

**Please provide a comment if you choose "Other":**

**c) CD4 cell count thresholds in children aged 5 years and older who are asymptomatic per MOH guidelines or directive::** regardless of CD4 count

**Please provide a comment if you choose "Other":**

**d) What is the practice in applying the CD4 threshold of 500 or regardless of CD4 count to initiate ART among children aged 5 years and older?:** Done country-wide

**Please provide a comment if you choose "Other":**

**7) Do national guidelines recommend ART for all HIV-infected patients with active TB?:** Yes

**Please provide a comment if you choose "Other":**

**8) Do national guidelines recommend ART for all HIV positive patients with Hepatitis B with severe liver disease?:** Yes

**Please provide a comment if you choose "Other":**

**9) Do national guidelines recommend ART for the HIV positive partner in sero-discordant couples?:** Yes

**If Other, please specify:**

**10) Do national guidelines recommend treating HIV positive persons identified as key populations\* irrespective of CD4 cell count? (Note that this is not currently a recommendation in the 2013 Consolidated ARV Guidelines):**  
Yes

**If yes, please specify the key population/s:**

**11) For which populations is nurse-initiated ART allowed?:** Pregnant Women

**Regimen**

**12) Is TDF/3TC or (FTC)/EFV the preferred 1st line ARV combination for treatment initiation in national guidelines among:**

**a) adults and adolescents:** Yes

**Please provide a comment if you choose "Other":**

**b) pregnant women:** Yes

**Please provide a comment if you choose "Other":**

**13) Does the country use fixed-dose ART combinations as the preferred first line therapy? :** Yes, one pill once a day

**Please provide a comment if you choose "Other":**

**14) Is there a policy to phase out D4T?**

**a) adults and adolescents:** Yes, partially phased out

**Please provide a comment if you choose "Other":**

**b) children:** Yes, partially phased out

**Please provide a comment if you choose "Other":**

**15) Is AZT/3TC (or FTC)/ATV/r(or LPV/r) the preferred 2nd line ARV combination for adults and adolescents with HIV in the national guidelines?:** Yes

**Please provide a comment if you choose "Other":**

**16) What is the preferred NRTI for treatment initiation for children with HIV less than 3 years of age?:** Zidovudine (AZT)

**If Other, please specify:**

**17) Are LPV/r based-regimens the preferred treatment option for all infants and children <36 months with HIV (irrespective of NNRTI exposure) in the national guidelines?:** Yes, for all

**18) Is Efavirenz (EFV) recommended as the preferred NNRTI for treatment initiation in children aged 3 years and older?:**

**If Other, please specify:**

**19) What is the recommended NRTI backbone for treatment initiation in children aged 3-10 years?:** AZT + 3TC (or FTC)

**If Other, please specify:**



**20) What is the recommended NRTI backbone for treatment initiation adolescents >35kg and at least 10 years of age?: AZT + 3TC (or FTC)**

**If Other, please specify:**

### **Monitoring treatment response**

**21) Does the country use point-of-care CD4 technology?: Yes**

**a) If yes, what proportion of district hospitals have CD4 testing capacity? Provide an estimate (%) :**

**b) What proportion of primary health care facilities have access to CD4 cell count for testing their patients, whether on-site or nearby referral)? Provide an estimate (%):**

**22) What is the current national policy and level of implementation of viral load?**

**a) Viral load policy for adults and the level of implementation:: Yes, fully implemented**

**If Yes (phase-in or fully-implemented), provide date:**

**b) Viral load policy for adolescents and the level of implementation:: Yes, fully implemented**

**If Yes (phase-in or fully-implemented), provide date:**

**c) The viral load policy for children and level of implementation:: Yes, fully implemented**

**If Yes (phase-in or fully-implemented), provide date:**

**23)What is the viral load testing strategy for monitoring the treatment response?**

**a) adults::**

**Routine first test at: : 6 months**

**Then follow up testing every: : 12 months**

**Targeted (based on suspected Non-response to ART):: Yes**

**b) adolescents: :**

**Routine first test at: : 3 months**

**Then follow up testing every: : 6 months**

**Targeted (based on suspected Non-response to ART):: Yes**

**c) children::**

**Routine first test at: : 3 months**

**Then follow up testing every: : 6 months**

**Targeted (based on suspected Non-response to ART)::** Yes

**24) What is the recommendation for viral load monitoring for:**

**a) adults ?:** Routine VL Monitoring

**If Other, please specify:**

**b) adolescents ? :** Routine VL Monitoring

**If Other, please specify:**

**c) children? :** Targeted VL

**If Other, please specify:**

**Service Delivery:**

**25) Which of the following service provision modalities are included in the ART national policy for:**

**a) adults?:** ART provision in TB clinics by TB providers

**If Other, please specify:**

**b) children?:** TB treatment in ART settings by ART providers

**If Other, please specify:**

**26) Which of the following co-infection policies are in place?**

**a) adults::** Isoniazid preventive therapy (IPT) for people living with HIV, Intensified TB case finding in PLHIV, TB Infection control for PLHIV, Co-trimoxazole prophylaxis, Hepatitis C diagnosis and management as part of HIV care, Hepatitis B and Hepatitis C testing in ART clinics, Hepatitis B vaccination provided at ART clinics, Hepatitis C treatment provided in ART clinics

**If Other, please specify:**

**b) children::** Isoniazid preventive therapy (IPT) for people living with HIV

**If Other, please specify:**

**C Prevention of Mother-to-Child Transmission**

**1) Do you have national plan for the elimination of MTCT of HIV?:** Yes

**If Yes, specify the MTCT transmission rate target(s) and year:** Less than 5% by 2015

**If Yes, specify the elimination target(s) (e.g. #cases/pop) and year:**

**2) Do you have a national plan for elimination of MTCT of syphilis?:** Yes, integrated with HIV or other elimination initiative

**3) What tests are used for screening pregnant women for syphilis in your country?**

**a) Laboratory-based Non-treponemal (e.g., RPR/VDRL):** No

**b) Laboratory-based treponemal (e.g., TPPA, TPHA):** Yes

**c) Rapid syphilis treponemal tests (e.g., Bioline, Determine, Chembio, etc.):** Yes

**4) What is the current nationally recommended PMTCT option? (as per MOH guidelines or directive)?:** Option B+

**If Option B or Option B+, please specify since when:** 2012

**5) What is the practice in applying the Option B+ in the treatment of HIV positive pregnant women?:** Done country-wide

**Please provide a comment if you choose "Other":**

**6) If currently implementing Option A, is transition to option B/B+ planned?:** No

**If Yes, please specify in what year:**

**7) What is the current nationally recommended first line ART regimen for pregnant and breastfeeding women with HIV?:** Other

**If Other, please specify:** TDF/3TC(FTC)

**8) What is the current nationally recommended PMTCT regimen, and duration, for exposed infants?**

**Current nationally recommended PMTCT regimen for exposed infants:** Nevirapine syrup

**Duration:** 6 weeks

**9) Is there a national recommendation on infant feeding for HIV-exposed infants?:** Yes - breastfeeding

**10) If breastfeeding is recommended for HIV positive women and exposed infants, is the duration specified?:** Yes

**If Yes, please specify the duration in months:** 12 months

## **D Sexually Transmitted Infections**

**1) Are there national STI treatment guidelines or recommendations? :** Yes

**If yes, what year were they last updated?:** 2012

**2) Does your country have a national strategy or action plan for the prevention and control of STI?:** Yes

**3) Is gonococcal antimicrobial resistance monitoring conducted in your country?:** Yes, less than annually

## **E Key populations**

**1) Which of the following key population or vulnerable groups are explicitly addressed in the national HIV policy or national plans?:** Adolescent key populations, Men who have sex with men, People in prisons and other closed settings, Sex workers (male and female)

**2) Do you have population size estimates for the following populations::** Adolescent key populations, Men who have sex with men, People in prisons and other closed settings, Sex workers (male and female)

**3) People who inject drugs: Which of the following components of the comprehensive package of HIV prevention, diagnosis, treatment and care interventions for people who inject drugs are implemented in your country?**

a) Needle and syringe programmes (NSP): No

b.i) Opioid substitution therapy (OST): No

b.ii) Other drug dependence treatment: No

c) Community provision of naloxone: No

d) HIV testing and counselling: No

e) Antiretroviral therapy: No

f) Sexually transmitted infection (STI) prevention and treatment: No

g) Comprehensive condom programming: No

h) Targeted information, education and communication (IEC): No

i) Viral hepatitis prevention, diagnosis, treatment and vaccination: No

j) Tuberculosis prevention, diagnosis and treatment: No

**4) People in prisons and other closed settings: Which of the following components of the comprehensive package of HIV prevention, diagnosis, treatment and care interventions for key populations are implemented in your country?**

a) Comprehensive condom and lubricant programming: Yes

b) harm reduction interventions for substance use (e.g. NSP and OST): No

c) behavioural interventions: Yes

d) HIV testing and counselling: Yes

e) HIV treatment and care: Yes

f) Co-infection and co-morbidity (viral hepatitis, tuberculosis, mental health) prevention and management: Yes

g) sexual and reproductive health interventions: Yes

**5) Sex Workers: Which of the following components of the comprehensive package of HIV prevention, diagnosis, treatment and care interventions for key populations are implemented in your country?**

a) Comprehensive condom and lubricant programming: Yes

**b) harm reduction interventions for substance use (e.g. NSP and OST):** No

**c) behavioural interventions:** Yes

**d) HIV testing and counselling:** Yes

**e) HIV treatment and care:** Yes

**f) Co-infection and co-morbidity (viral hepatitis, tuberculosis, mental health) prevention and management:** Yes

**g.i) Symptomatic STI treatment:** Yes

**g.ii) Screening for asymptomatic STI :** Yes

**g.iii) Periodic presumptive STI treatment:** No

**6) Men who have sex with men: Which of the following components of the comprehensive package of HIV prevention, diagnosis, treatment and care interventions for key populations are implemented in your country?**

**a) Comprehensive condom and lubricant programming:** Yes

**b) harm reduction interventions for substance use (e.g. NSP and OST):** No

**c) behavioural interventions:** Yes

**d) HIV testing and counselling:** Yes

**e) HIV treatment and care:** Yes

**f) Pre-exposure prophylaxis (PrEP):** No

**g) Co-infection and co-morbidity (viral hepatitis, tuberculosis, mental health) prevention and management:** Yes

**h.i) Symptomatic STI treatment:** Yes

**h.ii) Screening for asymptomatic STI:** Yes

**7) Transgender people: Which of the following components of the comprehensive package of HIV prevention, diagnosis, treatment and care interventions for key populations are implemented in your country?**

**a) Comprehensive condom and lubricant programming:** No

**b) harm reduction interventions for substance use (e.g. NSP and OST):** No

**c) behavioural interventions:** No

**d) HIV testing and counselling:** No

**e) HIV treatment and care:** No

**f) Co-infection and co-morbidity (viral hepatitis, tuberculosis, mental health) prevention and management:** No

**g.i) symptomatic STI treatment:** No

**g.ii) screening for asymptomatic STI:** No

## **F Male circumcision**

**1) What is the current timeframe and target age and number of voluntary medical male circumcisions to achieve?**

**Target number of voluntary medical male circumcisions:** 4,200,000

**Target age:** 15-49

**Target year:** 2011-2015

**2) What is the status of operational planning and monitoring?:** Operational plan for 2015 exists, Annual MC programme performance review conducted, MC HIV Prevention Programme is linked/(has a working plan) with adolescent health, A MC TWG/committee to review adverse events is established

**If Annual MC programme performance review has been conducted, please specify in what year:** 2013

**3) What are the recommended medical male circumcisions methods that are recommended/approved by the national programme?:** Conventional surgical methods (dorsal slit, forceps guided, sleeve resection), A prequalified device method has been approved for use

**If conventional surgical methods are recommended, please specify any age precisions:** The dorsal slit surgical method is for above 10 years

**If a prequalified device method has been approved for use, please specify:** Prepex has been pilot, finished active surveillance and now doing post surveillance.

## **G PrEP and PEP**

**1) Is PrEP being provided in the country?:** No

**If Yes, please specify for whom::**

**2) Is PEP being provided in the country?:** Yes

**If Yes, please specify for whom::** Victims of GBV, defilement, health care workers, rape and accident exposures.

**3) What drugs are recommended for:**

**a) Adults and adolescents: (please specify):** The approved first line combination therapy for adults

**b) Children: (please specify):** Approved first line combination therapy for children

**4) Number of prescriptions (for the reporting year)**

**a) Adults/adolescents:**

**b) Children:**

**5) Please provide reason/s for prescription (e.g. occupation, non-occupational etc.):**

## **H Surveillance**

### **1) Does the country carry out sentinel surveillance in special populations?**

**i) ANC attendees:** Yes

**if yes, please indicate:**

**Frequency in years:** Annual, but at times after every two years

**Number of sites:** 43

**Year of last survey:** 2013

**ii.a) Sex workers:** No

**if yes, please indicate:**

**Frequency in years:**

**Number of sites:**

**Year of last survey:**

**ii.b) People who inject drugs:** No

**if yes, please indicate:**

**Frequency in years:**

**Number of sites:**

**Year of last survey:**

**ii.c) Men who have sex with men:** No

**if yes, please indicate:**

**Frequency in years:**

**Number of sites:**

**Year of last survey:**

**ii.d) Transgender:** No

**if yes, please indicate:**

**Frequency in years:**

**Number of sites:**

**Year of last survey:**

**ii.e) In prisons and other closed settings:** No

**if yes, please indicate:**

**Frequency in years:**

**Number of sites:**

**Year of last survey:**

**Other specific populations:** No

**If yes, please specify the populations::**

**Frequency in years:**

**Number of sites:**

**Year of last survey:**

## **I Monitoring and evaluation**

### **1) What is the current status of planning for M&E of the HIV/AIDS health sector response?**

**A national M&E plan exists:** Yes

**If Yes, please specify the year it was last updated:** 2015

**A review of the M&E system was conducted:** Yes

**If Yes, please specify the year it was last reviewed:** 2014

**A review of the M&E system is planned:** Yes

**If Yes, please specify the year it is planned for:** 2017/18

## **J HIV Drug Resistance**

### **1) In the last 2 years, has the country carried out HIV Drug Resistance (HIVDR) surveillance according to the following WHO protocols?**

**a) Pretreatment drug resistance surveys:**

**if yes, please specify the year it was last started:**



**b) Acquired drug resistance surveys:**

**if yes, please specify the year it was last started:**

**c) Paediatric drug resistance surveys:**

**if yes, please specify the year it was last started:**

**d) Survey of clinic performance using early warning indicators for HIV drug resistance:**

**if yes, please specify the year it was last started:**

## **K Toxicity Monitoring Surveillance**

**1) Excluding passive pharmacovigilance approaches, is there a systematic effort ongoing to monitor the toxicity of ARVs in the country?:** No

**2) If Yes, what approaches are currently used? :**

## **L Strategic planning and review**

**If applicable, please provide the dates for the following:**

**1) Epidemiologic analysis:**

**a) When was the last epidemiological analysis conducted? (Please specify [month]/[year]):** December, 2014

**b) When is the next epidemiological analysis planned? (Please specify [month]/[year]):** December, 2015

**2) Programmatic and financial gap analysis:**

**a) When was the last programmatic and financial gap analysis conducted? (Please specify [month]/[year]):**  
December, 2014

**b) When is the next programmatic and financial gap analysis planned? (Please specify [month]/[year]):**  
December, 2015

**3) What is the status of national HIV/AIDS Programme development (that includes HIV in the health sector)?**

**The HIV national (health sector) strategic plan is in place:** Yes

**If yes, please specify validity: from (year):** 2015/16

**to (year):** 2019/2020

**The HIV (health sector) programme review was carried out:** No

**If Yes, please specify in which year:**

**The next HIV (health sector) programme review is planned:** Yes

**If Yes, please specify for which year:** 2016/17

**4) Does the current national HIV [health sector] strategy address the following elements::** Achieving universal access to ART,Collaboration between HIV and other services including reproductive health,Strengthening health systems,Reducing inequities

## M Reproductive Health and Research

**1) In your country, do you have service delivery points providing appropriate medical and psychological care and support for women and men who have been raped and experienced incest?:** No

### 0 Header

**is indicator/topic relevant?:** Yes

**Are new data available? (Please do not repeat data that was reported in a prior year):** No

**Data measurement tool / source:**

**Other measurement tool / source:**

**From date:**

**To date:**

**Additional information related to entered data. e.g. reference to primary data source, methodological concerns::**

**Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::**

### Survey to document the data situation in 2014

Download the 2015 questionnaire, [2015-ARV SURVEY en.doc](#)

Then, upload the filled-in form using the "Add file" button.

### 3.12 ANC and EID Facilities

**is indicator/topic relevant?:** Yes

**Are new data available? (Please do not repeat data that was reported in a prior year):** Yes

**Data measurement tool / source:** Other (please specify)

**Other measurement tool / source:** HMIS

**From date:** 01/01/2014

**To date:** 31/12/2014

**Additional information related to entered data. e.g. reference to primary data source, methodological concerns::**

**Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::**

#### 3.12.1 Number of antenatal care facilities providing HIV testing and counselling services

	Data value
<b>Number of antenatal care facilities providing HIV testing and counselling services - Total</b>	3028
<b>Public sector</b>	
<b>Private sector</b>	
<b>Unknown</b>	

#### 3.12.2 Number of antenatal care facilities providing HIV testing and counselling services and dispensing antiretrovirals

	Data value
<b>Number of antenatal care facilities providing HIV testing and counselling services and dispensing antiretrovirals - Total</b>	1976
<b>Public sector</b>	
<b>Private sector</b>	
<b>Unknown</b>	

### 3.12.3 Percentage of health facilities that provide virological testing services (e.g. polymerase chain reaction) for diagnosis of HIV in infants on site or from dried blood spots

	Data value
<b>Percentage (%)</b> : Percentage of health facilities that provide virological testing services (e.g. polymerase chain reaction) for diagnosis of HIV in infants on site or from dried blood spots	
<b>Numerator</b> : Number of health facilities that provide virological testing services (e.g. PCR) for diagnosis of HIV in infants on site or from dried blood spots (DBS)	
<b>On site</b>	
<b>Through dried blood spots (DBS)</b>	
<b>Other/uncategorized</b> : please specify the period in the comment field	
<b>Denominator</b> : Total number of health facilities that provide follow-up for HIV exposed infants	